|
Indian Pediatr 2017;54: 913-918 |
|
Outcome of 200 Pediatric Living Donor Liver
Transplantations in India
|
Neelam Mohan, Sakshi Karkra,
#Amit Rastogi, *Maninder
S Dhaliwal, *Veena Raghunathan, Deepak Goyal,
#Sanjay Goja ,
#Prashant Bhangui ,
#Vijay Vohra,
$Tarun Piplani,
$Vivek Sharma,
#Dheeraj Gautam,
$SS Baijal and
#AS Soin
Department of Pediatric Gastroenterology, Hepatology
and Liver transplant, *Pediatric Intensive Care Unit, #Institute
of Liver Transplant and Regenerative Medicine, and $Department
of Radiology; Medanta –The Medicity, Gurgaon, Haryana, India.
Correspondence to: Neelam Mohan, Department of
Pediatric Gastroenterology, Hepatology and Liver transplant, Medanta –
The Medicity, Gurgaon, Haryana, India.
Email: [email protected]
Received: August 23, 2016;
Initial Review: March 14, 2017;
Accepted: July 26, 2017.
Published online:
August 24, 2017.
PII:S097475591600083
|
Objective: To describe our experience of pediatric living donor
liver transplantation from India over a period of 12 years.
Materials and Methods: A
retrospective analysis of 200 living donor liver transplantation in
children (18 years or younger) was done for demographic features,
indications, donor and graft profile and outcome.
Results: Between September 2004
and July 2016, 200 liver transplants were performed on 197 children.
Fifty transplants were done in initial 6 years and 150 in next 6 years.
All donors (51% mothers) were discharged with a mean stay of 7 days. The
leading indications of liver transplants were cholestatic liver disease
(46%) followed by metabolic liver disease (33%) and acute liver
failure/acute on chronic liver failure (28.5%). Biliary leakage (8.5%),
biliary stricture (9%), hepatic artery thrombosis (4.5%) and portal vein
thrombosis (4%) were the most common surgical complications; all could
be managed by surgical or interventional radiological measures, except
in one child who died. Sepsis, acute rejection and CMV hepatitis in
first 6 months were seen in 14.5%, 25% and 17% cases, respectively.
Post-transplant lymphoproliferative disease was seen in only 1.5%.
Re-transplant rate was 1.5%. The overall 1 year survival rate was 94%
and 5 year actuarial survival was 87% with no statistically significant
difference between children weight <10 kg vs. >10 kg. Outcome in acute
liver failure did not differ significantly between those with acute on
chronic liver failure vs. those with chronic liver disease.
Conclusions: Advances in medical
and surgical techniques associated with multidisciplinary teams
including skilled pediatric liver transplant surgeons, anesthetists,
dedicated pediatric hepatologists, pediatric intensivists,
interventional radiologists and pathologists resulted in an excellent
outcome of living related liver transplants in children. Low age and
weight of the baby does not seem to be a contraindication for liver
transplantation as outcome were comparable in our experience.
Key words: Acute Liver failure, Biliary
Atresia, Metabolic liver disease, Domino liver transplant.
|
L iver transplantation (LT) has
been well established in India for more than a decade now [1]. Common
indications of pediatric LT are chronic liver disease (cholestatic,
metabolic, autoimmune), acute liver failure and liver tumors. Over the
years, the indications have extended to various inborn errors of
metabolism [2]. We present our experience of 200 pediatric living donor
liver transplantations (LDLT).
Methods
Data were collected from records of 200 children (<18
years of age) who underwent LDLT from September 2004 to July 2016. The
initial 50 transplants were performed by the same team of surgeons and
hepatologists at Sir Ganga Ram Hospital (New Delhi), and subsequent 150
transplants were performed at Medanta the Medicity (Gurgaon - Haryana).
Data was collected on age, sex, blood group,
underlying liver disease, indications for liver transplant, vaccination
status, and pre- and post-transplant cytomegalovirus (CMV) and Ebstein
Barr virus (EBV) serology status of the patient. Outcomes were recorded
in terms of rejection (acute/chronic), surgical complications, blood
culture positive sepsis, CMV hepatitis in the first 3 months,
post-transplant lymphoproliferative disease (PTLD), re-transplantation,
and survival. ALF was defined as per Pediatric Acute Liver Failure
(PALF) study group as biochemical evidence of acute liver injury in a
child with no known evidence of Chronic liver disease (CLD) with
coagulopathy (defined as prothrombin time (PT)
³15
sec or INR
³1.5
not corrected by Vitamin K in the presence of encephalopathy, or PT >20
sec and INR >2.0 in patients without encephalopathy) [3]. Patients who
had hepatic insult manifesting as jaundice and coagulopathy complicated
within 4 weeks by ascites or encephalopathy in a previously diagnosed or
undiagnosed CLD, were classified as having Acute on chronic liver
failure (ACLF) as per Asia Pacific guidelines [4].
The criteria for listing for LT in patients with CLD
included pediatric end stage liver disease (PELD) score >10 age <12
years, and model for end-stage liver disease (MELD) score >15 in >12
years, as per AASLD guidelines [4]. Those patients with ALF who
fulfilled King’s College criteria and revised Wilson’s prognostic index
for Wilson’s disease (WD) were listed for LDLT. However, the trend of
INR either outside or within hospital was followed before proceeding for
LT. None of the patients with INR <4 were transplanted. Significant
portal hypertension not responding to medications or associated moderate
to severe hepatopulmonary syndrome with more than 20% shunt were listed
irrespective of their PELD or MELD score [4]. Patients with organic
acidemias, urea cycle disorders and factor VII deficiencies were
excluded from PELD and MELD scoring criteria for transplantation [5].
The immunization of the patients with CLD included
all vaccines as per Indian Academy of Pediatrics (IAP) guidelines along
with few optional vaccines such as hepatitis A, pneumococcal, chickenpox
and typhoid. Our protocol included Measles Mumps Rubella (MMR) vaccine
at 6 months, if early transplant was attempted. Live vaccines were not
given within 3 weeks prior to the LT [6]. Nutritional assessment was
done by measuring weight and height (centile and Z score as per
WHO standards). In patients of CLD with associated malnutrition posted
for elective LT, efforts were made for nutritional optimization for 3-8
weeks prior to transplant, depending on the clinical condition of the
patient. Energy-dense (120-150 kcal) and high protein diets were
initiated in all, and if required tube feeds were given in hospitalized
patients. However, weight and vaccination was not a criterion to refuse
transplant in cases with advanced liver disease/liver failure
necessitating urgent LT.
As per Government of India guidelines, all
transplants were performed with related donors. Blood group matched
liver donors were preferred. In the absence of suitable blood group or
volume mismatch in the family members, swap transplantation was done,
which means paired donor exchange thus benefitting both patients. In the
absence of suitable swap transplantation, ABO mismatch LT was done.
Immunosuppression protocol in all patients included triple
immunosuppression which comprised of steroids (day 1), tacrolimus (day
3) and mycophenolate (day 3-5) unless any toxicity was observed to that
drug. Tacrolimus level of 7-10 ng/mL was maintained in the initial 1-2
months, followed by gradual tapering of the dose over time to achieve
long term immuno-suppression levels of 4-6 ng/mL beyond 1 year post-LT.
Mycophenolate was stopped 6-7 months post-LT in most patients.
Antibiotic prophylaxis with broad spectrum antibiotics and antifungal
prophylaxis with fluconazole were utilized in all children. Antiviral
prophylaxis for CMV with intravenous gancyclovir or oral valgancyclovir
was administered for initial one month post-transplant in high-risk
cases (donor positive and recipient negative cases, patients who were
CMV PCR positive prior to transplant, and in all infants in last 100
transplants). In the last 150 liver transplants, CMV and EBV PCR
(quantitative) monitoring was done at 2, 4, 8, 12 and 24 weeks post-LT
followed by 6-monthly intervals or as and when viremia was suspected.
Ultrasound-Doppler for hepatic vasculature was done twice-a-day for
first 5 days post-LT; then daily till 7-10 days post-surgery following
which a protocol of twice-a-week was followed till discharge.
The donors underwent a complete medical and physical
examination as per standard international living liver donation
guidelines [7]. The following donor data was obtained from database:
age, sex, blood group, relationship to recipient, graft type and outcome
in terms of complications and survival.
Statistical analysis: The patient survival is
shown as Kaplan Meier curve, and comparison between different groups was
performed using log rank tests. Categorical and continuous variables
were compared using Fisher’s exact test, the Mann-Whitney U test, and t
test, respectively. P<0.05 was considered statistically
significant. Statistical analysis was performed with the SPSS version
19.0.
Results
A total of 200 LDLT, including three re-transplants,
were performed on 197 patients (60% males). Indications of LDLT are
shown in Table I. Biliary atresia (BA) was the commonest
indication for liver transplant. Forty-eight (66%) BA patients had
undergone Kasai Portoentero-stomy prior to transplant. Majority of WD
cases had an ALF- or ACLF-like presentation. Three of them were unmasked
by acute hepatitis A or E infection. Out of the three tyrosinemia cases
presenting as ACLF, two had associated CMV infection as an acute event
and one had associated hepatitis A infection.
TABLE I Indications of Liver Transplant (N=200).
Indication
|
Number
|
Chronic liver disease
|
133
|
Biliary atresia
|
72 (75%)
|
Progressive Familial Intrahepatic Cholestasis
|
10
|
Caroli disease
|
2
|
Allagille syndrome
|
3
|
Sclerosing Cholangitis (LCH)
|
3
|
Choledochal cyst IV
|
1 |
Budd- Chiari Syndrome
|
3 |
Portal Biliopathy with Biliary cirrhosis
|
1
|
Chronic Rejection with Biliary cirrhosis
|
1 |
Autoimmune hepatitis
|
15
|
Chronic hepatitis B
|
1 |
Wilsons disease
|
5
|
Tyrosinemia
|
7 |
Glycogen storage disease
|
1
|
Cryptogenic
|
8 |
Acute Liver Failure#
|
57
|
Hepatitis A virus
|
8 |
Hepatitis E virus
|
3 |
Cryptogenic
|
13
|
Wilsons
|
24
|
Autoimmune
|
8
|
Tyrosinemia
|
5 |
Neonatal hemachromatosis
|
1 |
Drug (anti-tubercular drugs)
|
1 |
Tumours
|
2 |
Giant cavernous hemangioma
|
1 |
Hepatoblastoma
|
1 |
Others
|
8
|
Primary hyperoxaluria 1
|
2 |
Maple syrup urine disease |
2 |
Citrullinemia type 1 |
3 |
Factor VII deficiency |
1 |
#including 33 patient with acute on
chronic liver failure. |
Of the 200 transplants, there were 2 domino donors.
These domino donors were 2-and 3- year-old maple syrup urine disease
(MSUD) cases whose explanted whole liver was used as a graft for
children with biliary cirrhosis. Out of 217 potential donors evaluated
for 198 liver transplants, four were medically unfit and 15 were
rejected because of fatty liver. The characteristics of recipients and
donors are shown in Table II. Majority (61%) of donors
were females. The median (IQR) age and weight of donors were 34.7 (29,
40) years and 65.4 (58, 74) kg, respectively. Majority (51%) of donors
were mothers, followed by close relatives (26%), father (18%) and swap
donors (3.5%). Almost three-fourths (77.5%, n=155) donor were of
same blood group as recipient, 21% (n=42) had compatible but
non-identical blood group, and 3 (1.5%) had incompatible blood group.
The median hospital stay for donors was 7 days. There were no major
complications in them, except for biliary leak in two, which was managed
conservatively and an incision hernia in one which was repaired
surgically.
TABLE II Characteristics of the Recipients and Grafts
Recipient |
Total
|
Chronic liver disease#
|
Acute liver failure
|
Acute on chronic liver
|
Others
|
|
(n=200) |
(n=133) |
(n=24) |
failure (n=33) |
(n=10)
|
Male/female |
120/80 |
76/56 |
18/6 |
19/14 |
7/3 |
Median (IQR) age (mo)
|
60 (17-112) |
28 (12-96) |
90 (63-146) |
108 (83-120) |
34 (18-84) |
Median (IQR) weight (kg) |
16 (9-27)
|
12 (8-21) |
25.5 (20-40) |
25 (19-36.5) |
12 (9.5-19.7) |
Z score (weight) |
0.020 |
-0.102 |
0.498 |
0.235 |
0.166 |
Z score (height) |
0.459 |
0.399 |
0.994 |
0.236 |
0.625 |
Left lateral segment, n (%)
|
78 (39%) |
60 |
5 |
8 |
5 |
Reduced graft, n (%) |
26 (13%) |
22 |
3 |
1 |
- |
Left lobe, n (%) |
68 (34%) |
36 |
10 |
18 |
4 |
Right lobe, n (%) |
26 (13%) |
13 |
6 |
6 |
1 |
Domino, n (%) |
2 (1%) |
2 |
- |
- |
- |
Median (IQR) stay (d) |
21 (5-90) |
21(18-28) |
20 (17-25) |
23 (17-25) |
24 (20-32) |
#2 patients with liver tumors were ‘grouped’ in
others. |
Median age and weight in CLD group (Table
II) was significantly less as compared to patients in ALF (P<0.001)
and ACLF group (P £0.001)
with no statistically significant difference between ALF and ACLF. Mean
PELD score in children<12 years of age was 21.5, and mean MELD in >12
years was 27. The mean (range) INR in ALF group was 8.1 (4.3-14).
Pre-transplant CMV IgG and EBV IgG were positive in 90% and 74% of
recipients, excluding initial 60 transplants where these were not done.
There was no significant difference in mean hospital stay between the
various groups. Graft details are given in Table II. A
total of 63 patients weighed <10 kg and nearly half of them received
reduced left lateral segments. Gore-Tex mesh closure of the abdominal
wall, followed by delayed closure 2 weeks later, was done in three of
our patients who weighed <6 kg.
Blood culture positive sepsis was seen in 14.5%
patients, of which 8 patients (27%) died and rest responded to
antibiotics. Majority (76%) of these were multidrug-resistant gram
negative organisms (Klebsiella pneumoniae 9, Acinetobacter
baumannii 7, Burkholderia cepacia 3, Salmonella paratyphi
1 and Pseudomonas aeruginosa 2) followed by gram positive
cocci in 20% (Enterococcus faecium 3 and Staphylococcus 5)
and Candida (n=2). There was no statistically significant
difference in the incidence of sepsis in ALF versus decompensated
CLD (P=0.23) or <10 kg vs more than 10 kg patients (P=0.5).
CMV hepatitis occurred in 34 (17%) children and all responded to
gancyclovir. The incidence of CMV hepatitis was higher (P=0.041)
in children age <2 years (22.5%) in comparison to older age. Acute
rejection during the first 4 weeks post-LT was seen in 25% of our
patients, of which 64% were biopsy proven. All responded to pulse
steroid therapy except one who required anti thymocyte globulin (ATG)
but still progressed to chronic rejection. Drug-induced complications in
the postoperative period included transient hyperglycemia and
hypertension in 22% and 29%, respectively. Clinical seizures in
immediate post-transplant period were seen in 10% of our patients, all
of whom responded to anticonvulsants and the medications were stopped
within 3 months. Two of these patients had changes suggestive of
Posterior reversible encephalopathy syndrome (PRES) on neuroimaging, and
responded well to antihypertensive therapy. Late complications in our
series included PTLD in 3 patients (2 of them had EBV viremia within 6
months post-LT while one developed Burkitt’s lymphoma 2 year post-LT
with no EBV viremia). Two of these PTLD patients died, including the
child with Burkitt’s lymphoma in whom parents refused chemotherapy; one
recovered with use of Rituximab and is doing well on more than 5 year
follow-up. Chronic rejection was seen in five patients; three died, one
underwent retransplant and another one responded to modified
immunosuppression. Recurrence of autoimmune hepatitis post-LT was seen
in 2 of 23 patients (8.6%) with one retransplant being done in a case of
autoimmune hepatitis with sclerosing cholangitis within 2 years of
primary transplant. She is doing well 3 years after second transplant.
Biliary and vascular complications were among the
most common surgical complications. Seventeen (8.5%) children developed
biliary leak and 18 (9%) developed biliary stricture at the anastomotic
site. Biliary complications could be addressed conservatively /by
interventional radiology/surgery with good outcome. Vascular
complications included hepatic artery thrombosis in 9 (4.5%) and portal
vein thrombosis in 8(4%) patients. Two patients with hepatic artery
thrombosis died while rest of the patients with vascular complications
could be successfully managed by surgical /interventional radiological
techniques. Bowel perforation requiring laparotomy was observed in 9
patients. Eight of these patients were post-Kasai who had severe
intraabdominal adhesions noted at the time of transplant. One patient
had perforation secondary to sepsis and intussusception. Chylous ascites
was seen in 15 patients. All recovered on medium-chain-triglycerides
(MCT)-based dietary therapy within 3 weeks except one in whom
improvement was seen over 10 weeks. In 7 of these 15 patients, total
parenteral nutrition was used in the first week of onset of chylous
ascites.
Re-transplants were done in three patients. These
were done for hepatic artery thrombosis, recurrence of autoimmune
disease and chronic rejection at 4 weeks, 2 years and 4 years
post-primary LT, respectively. In our series of 200 liver transplants,
19 recipients died (9.5%). Death within 4 weeks of surgery was seen in 9
(<5%); 1 due to hepatic artery thrombosis, 1 due to massive intracranial
bleed in a case of hepatopulmonary syndrome, 2 patients of WD-related
acute kidney injury, 5 due to sepsis. Another 5% died beyond 1 month
post-LT; 3 due to sepsis, 2 with PTLD, 3 with chronic rejection, 1 with
disseminated tuberculosis, and 1 with bleeding from ectopic varices
despite PV stenting. There were 2 patients on high dose of tacrolimus
beyond 1 year post-LT who developed diabetes requiring insulin, which
responded to reduction of tacrolimus and use of mycophenolate mofetil.
Our overall patient- and graft-survival rates were 90.5% and 89%,
respectively. Actuarial survival at 1 and 5 year was 94% and 87%,
respectively (Web Fig. 1a).
The actuarial 5-year survival in age <1 yr was 84% in comparison to
91.5% in age >1 year (P=0.08). The survival was 100% for ALF,
90.4% for CLD and 85% for ACLF (Web Fig.
1b). There was no significant difference in survival between
these groups (P=0.375).
Discussion
In majority of our cases mothers were the donor. To
answer organ shortage we did swap and ABO incompatible LT. We did 2
domino LT from grafts of our MSUD patients [8].
The leading indications of pediatric LT at our center
were BA followed by metabolic liver disease (MLD) and ALF. Biliary
atresias followed by MLD were also the commonest indications in 808
children transplanted in Pittsburgh [9]. Data from Southern India by
Safwan, et al. [10] reported a primary LT in 43% of their series
of 58 children with BA, suggesting delayed referral as a major issue in
management of BA in India. However, in another study from Northern India
on 20 BA children undergoing LDLT [11], primary LT was done in only 10%
cases.
Biliary complications including bile leak and
anastomotic stricture have historically been a major problem of partial
liver grafts resulting from very small/multiple bile ducts or thrombosis
of hepatic artery. Technical surgical advances have significantly
lowered these complications. Studies from India, USA and Japan have
reported an overall incidence of 6-27% bile leaks after LDLT [12].
Mesquita, et al. [13] reported biliary complication rate as low
as 7.5%. This may be due to the fact that their patients were older
(mean age of 6 years) in comparison to those in our series.
In our study, incidence of hepatic artery thrombosis
was relatively low (4.5%) and all except two cases could be salvaged by
innovative surgical techniques. Recent studies from New York and Brazil
had vascular complications ranging from 12-31% [14,15]. The high-risk
factors for this, as discussed in literature include children <3 years
of age and weight <15 kg [16]. Reported incidence of portal vein
thrombosis in pediatric LT is 44-12% [17,18]. In our series, we had 4%
incidence, and 92% of these cases were post-Kasai BA. The portal vein in
children, especially after a Kasai procedure, is often narrow, fibrotic
or encased in inflammatory lymph nodes causing high risk of PVT. We had
4.5% enteric perforations; all but one occurred in post- Kasai patients
with repeated cholangitis and ascites, suggesting that previous surgery
and abdominal infections are high-risk cases.
The incidence of CMV / EBV infection and PTLD was low
in our series as compared to 4-15% in western literature [19]. Most of
our patients and donors were CMV IgG and EBV IgG positive, thus were at
relatively low risk.
With good infection control policies, blood culture
positive sepsis rate at our center was low (14.5%). Varghese, et al.
[20] in a series of 35 liver transplant patients from Chennai reported
sepsis in 20%. Other centers from Korea and France have reported blood
culture positive infections in about one-third of their patients post-LT
[21,22]. We upgraded antibiotics empirically on clinical suspicion of
sepsis; this could probably have lead to poor blood culture yield. We
found a higher incidence of infection with gram negative organisms
similar to observations by Varghese, et al. [20], whereas
Western centers have reported higher incidence of infection with gram
positive bacteria [22]. Sepsis was the cause in 42% of our deaths, which
is similar to the finding by Ueda, et al. [23] from Japan.
Incidence of acute rejection in DDLT (Deceased Donor Liver Transplant)
has been reported between 40% to 70% while in LDLT it is less, ranging
from 15-30% [24]. In our series, acute rejection was seen in 25%
responding to pulse steroid therapy in all but one patient. Chronic
rejection was seen in 2.5% of our patients, and in most it was due to
poor compliance with drugs, especially in adolescent age. We added
Sirolimus in them with no great benefit.
Survival rates in our patients was at par with busy
pediatric transplant centers in the world [25]. In our study, outcome
was 100% in patients undergoing emergency transplant for ALF. In our
setup, the donor work-up could be done within 6-8 hours if required. We
used KCH criteria which have been shown to have a better performance
than the Clichy criteria and is widely used. The KCH criteria appear to
have a higher specificity than sensitivity for acetaminophen-induced
ALF, while its negative predictive value for non-acetaminophen induced
ALF is low. We always looked at the trend of INR either outside/inside
the hospital before proceeding for LT.
Limitation of our study is that nutrition assessment
was based on weight and height Z score and not by the preferred modality
in CLD patients of assessing muscle mass and skin fold thicknesses.
Post-transplant nutritional status and quality of life was not addressed
in this study. Retrospective nature of data is also a potential
limitation.
We conclude that LDLT is an available modality of
treatment for ESLD, inborn errors of metabolism and ALF in Indian
setting with outcomes comparable with the best centers of world.
Morbidity and mortality due to vascular, biliary complications and
sepsis post-liver transplant have reduced due to technical and medical
advances. Multidisciplinary involvement from trained pediatric LT
surgeons, hepatologists, anesthetists, intensivists, interventional
radiologists and pathologists has lead to a good outcome.
Contributors: NM – Interpretation of data,
drafting and editing the manuscript; SK- Data analysis and drafting of
manuscript; AR, MS, VR, DG, SG, PB, VV – Helping in management of
patient and revision of manuscript; VS, TP , SSB – In analysis of
radiology data; DG – reviewed the biopsy slides; AS – Transplant surgeon
and critical revision of manuscript. All authors approved the final
version of manuscript.
Funding: None. Competing interest: None
stated.
References
1. Sibal A, Bhatia V, Gupta S. Fifteen years of liver
transplantation in India. Indian Pediatr. 2013; 50: 999-1000.
2. Alam S, Sood V. Metabolic liver disease presenting
as acute liver failure in children. Indian Pediatr. 2016;53: 695-701.
3. Squires R H, Shneider B L, Bucuvalas J, Alonso E
, Sokol R J, Narkewicz M R, et al. Acute liver failure in
children: The first 348 patients in the pediatric acute liver Failure
study group. J Pediatr. 2006;148:652-8.
4. Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari
C, Chan AC. Acute-on-chronic liver failure: Consensus recommendations of
the Asian Pacific Association for the Study of the Liver (APASL) 2014.
Hepatol Int. 2014;8:453-71.
5. Squires RH, Ng V, Romero R, Ekong U, Hardikar W,
Emre S, et al. Evaluation of the pediatric patient for liver
transplantation: 2014 practice guideline by the American
association for the study of liver diseases, American society of
transplantation and the North American society for pediatric
gastroenterology, hepatology and nutrition. Hepatology. 2014;60:362-98.
6. Danzinger-Isakov L, Kumar D. Guidelines for
vaccination of solid organ transplant candidates and recipients. Am J
Transplant. 2009;9:S258-62.
7. Miller CM, Durand F, Heimbach JK, Kim Schluger L,
Lee SG, Lerut J, et al. The International Liver Transplant
Society Guideline on living liver donation. Transplantation.
2016;100:1238-43.
8. Mohan N, Karkra S, Rastogi A, Vohra VK, Soin AS.
Living donor liver transplantation in maple syrup urine disease. Case
series and world’s youngest domino liver donor and recipient. Pediatric
Transplant. 2016;20: 395-400.
9. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris
AJ, Ruppert K, et al. Long-term survival after liver
transplantation in 4,000 consecutive patients at a single center. Ann.
Surg. 2000;232:490-500.
10. Safwan M, Ramachandran P, Reddy MS, Shanmugam N,
Rela M. Living donor liver transplantation for biliary atresia — an
Indian experience. Pediatr Transplant. 2016; 20:1045-50.
11. Malhotra S, Sibal A, Bhatia V, Kapoor A, Gopalan
S, Seth S, et al. Living related liver transplantation for
biliary atresia in the last 5 years: Experience from the first liver
transplant program in India. Indian J Pediatr. 2015;82: 884-9.
12. Wadhawan M, Kumar A, Gupta S, Goyal N, Shandil R,
Taneja S, et al. Post-transplant biliary complications: An
analysis from a predominantly living donor liver transplant center. J
Gastroenterol Hepatol. 2013;28: 1056-60.
13. Mesquita MC, Ferreira AR, Veloso LF, Roquete
ML, Lima AS, Pimenta JR, et al. Pediatric liver transplantation:
10 years of experience at a single center in Brazil. J Pediatr (Rio J).
2008;84:395-402.
14. Miller CM, Gabriel EG, Sander F, Cal M, Luis M,
Tomoharu Y, et al. One Hundred nine living donor liver
transplants in adults and children: A single-center experience. Ann.
Surg. 2001;234:301-12.
15. Chardot C, Buet C, Serinet MO, Golmard JL,
Lachaux A, Roquelaure B, et al. Improving outcomes of biliary
atresia: French national series 1986-2009. J Hepatol. 2013;58:1209.
16. Ueda M, Egawa H, Ogawa K. Portal vein
complications in the long-term course after pediatric living donor liver
transplantation. Transplant Proc. 2005; 37:1138.
17. Kelly DA, Bucuvalas JC, Alonso EM, Karpen SJ,
Allen U, Green M, et al. Long-term medical management of the
pediatric patient after liver transplantation: 2013 Practice Guideline
by the American Association for the Study of Liver Diseases and the
American Society of Transplantation. Liver Transplant. 2013;19:798-825.
18. Cacciarelli TV, Esquivel CO, Moore DH, Cox
KL, Berquist WE, Concepcion W, et al. Factors affecting survival
after orthotopic liver transplantation in infants. Trans-plantation.
1997;64:242-8.
19. Taylor AL, Marcus R, Bradley JA. Post-transplant
lymphoproliferative disorders (PTLD) after solid organ
transplantation. Crit Rev Oncol Hematol. 2005;56: 155-167.
20. Varghese J, Gomathy N, Rajashekhar P, Venugopal
K, Olithselvan A, Vivekanandan S, et al. Perioperative bacterial
infections in deceased donor and living donor liver transplant
recipients. J Clin Exp Hepatol. 2012; 2:35-41.
21. Kim JE, Oh SH, Kim KM, Choi BH, Kim DY, Cho HR,
et al. Infections after living donor liver transplantation in
children. J Korean Med Sci. 2010;25:527-31.
22. Bouchut JC, Stamm D, Boillot O, Lepape A, Floret
D. Postoperative infectious complications in pediatric liver
transplantation: A study of 48 transplants. Paediatr
Anaesth. 2001;11:93-8.
23. Ueda M, Oike F, Ogura Y, Uryuhara K, Fujimoto Y,
Kasahara M et al. Long-term outcomes of 600 living donor liver
transplants for pediatric patients at a single center. Liver Transpl.
2006; 12:1326-36.
24. Rao S, D’Cruz ALJ, Aggarwal R, Chandrashekar S,
Chetan G, Gopalakrishnan G, et al. Pediatric liver
transplantation: A report from a pediatric surgical unit. J Indian Assoc
Pediatr Surg. 2011;16:2-7.
25. Byun J, Yi NJ, Lee JM, Suh SW, Yoo T, Choi Y, et al. Long
term outcomes of pediatric liver transplantation according to age. J
Korean Med Sci. 2014;29:320-7.
|
|
|
|